Astec Lifesciences Ltd
NSE:ASTEC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
827.75
1 458.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Astec Lifesciences Ltd
Cost of Revenue
Astec Lifesciences Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Astec Lifesciences Ltd
NSE:ASTEC
|
Cost of Revenue
-₹3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-8%
|
|
|
UPL Ltd
NSE:UPL
|
Cost of Revenue
-₹250.8B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-16%
|
|
|
Fertilisers And Chemicals Travancore Ltd
NSE:FACT
|
Cost of Revenue
-₹33.1B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Bayer Cropscience Ltd
NSE:BAYERCROP
|
Cost of Revenue
-₹29.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
PI Industries Ltd
NSE:PIIND
|
Cost of Revenue
-₹38.1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Coromandel International Ltd
NSE:COROMANDEL
|
Cost of Revenue
-₹161.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-8%
|
|
Astec Lifesciences Ltd
Glance View
Astec LifeSciences Ltd. engages in the manufacture and sale of agrochemicals and pharmaceutical intermediates. The company is headquartered in Mumbai, Maharashtra and currently employs 506 full-time employees. The company went IPO on 2009-11-25. The firm operates through the Agrochemicals segment. The company manufactures a range of fungicides, insecticides, herbicides and intermediates for its global customers. The Company’s product and intermediates include triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, silane derivatives, fluorinated aromatic, aliphatic and heterocyclic intermediates, fluorinated aromatic amines, fluorinated pyridine derivatives, fluorinated aromatic carboxylic acids, fluorinated benzyl alcohols, fluorinated ketones and benzophenones, fluorinated heterocyclic mercaptans, heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans and heterocyclic sulfonyl chlorides. The company has two multipurpose production sites at Mahad.
See Also
What is Astec Lifesciences Ltd's Cost of Revenue?
Cost of Revenue
-3B
INR
Based on the financial report for Sep 30, 2024, Astec Lifesciences Ltd's Cost of Revenue amounts to -3B INR.
What is Astec Lifesciences Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-8%
Over the last year, the Cost of Revenue growth was 10%. The average annual Cost of Revenue growth rates for Astec Lifesciences Ltd have been 1% over the past three years , 1% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet
